Palvella Therapeutics initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $45 price target The company’s Qtorin platform delivers drugs to the skin for rare derm indications, starting with a topical re-formulation of sirolimus for cutaneous mTOR-driven disorders, the analyst tells investors in a research note. The firm likes like Palvella’s approach to micro microcystic lymphatic malformations.